{"entity":{"id":"nct06118086","kind":"trial","name":"Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma","aka":[],"tldr":"A phase 1/2 trial of REM-422 in salivary gland cancers, run by Remix Therapeutics, now recruiting.","summary":"Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma is a phase 1/2 interventional study registered as NCT06118086 by Remix Therapeutics, with 125 participants planned, started 2023-12-20 and due to reach its primary completion in 2027-09-30. Interventions recorded: REM-422.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06118086","url":"https://clinicaltrials.gov/study/NCT06118086"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["salivary-gland"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06118086","phase":"1/2","setting":"A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma","sponsor":"Remix Therapeutics","enrolled":125,"outcomes":[]},"route":"/trials/nct06118086/","neighbours":{"cancer":[{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/"}],"drug":[{"id":"rem-422","kind":"drug","name":"REM-422","route":"/drugs/rem-422/"}]}}